You are here: Industry Insights > NSCLC

News List

FDA approves CYRAMZA® (ramucirumab) for EGFR-mutated non-small cell lung cancer europeanpharmaceuticalreview
June 02, 2020
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastati pharmaceutical-business-review
May 29, 2020
Bristol Myers Squibb announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy was approved by the U.S. Food and Drug Administration (FDA) ...
US FDA approves Takeda’s ALUNBRIG for rare and serious form of lung cancer pharmaceutical-business-review
May 28, 2020
Takeda Pharmaceutical Company announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) ...
AZ links with ArcherDX to detect minimal residual disease in lung cancer patients pharmatimes
May 27, 2020
AstraZeneca is teaming up with genomic analysis group ArcherDX to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC).
New US approval for Takeda’s Alunbrig pharmatimes
May 26, 2020
US regulators have expanded the scope of Takeda's Alunbrig (brigatinib) to include first-line treatment of adults with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCL pharmaceutical-business-review
May 21, 2020
Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC).
Janssen Announces Phase 1 Results for Amivantamab for Advanced NSCLC americanpharmaceuticalreview
May 21, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 1 CHRYSALIS study.
New US nod for Roche's Tecentriq in NSCLC pharmatimes
May 20, 2020
The US Food and Drug Administration has approved Roche's Tecentriq (atezolizumab) as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression ...
AstraZeneca gets breakthrough status for Enhertu to treat NSCLC pharmaceutical-technology
May 20, 2020
AstraZeneca and its partner Daiichi Sankyo have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for Enhertu (trastuzumab deruxtecan) to treat non-small cell lung cancer (NSCLC).
AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation pharmatimes
May 19, 2020
AstraZeneca's and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with a particular form of lung cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page